Media

Safer Psychedelic Drugs May Be Coming

MDMA Drug Developers Reprioritize Following Lykos Rejection in PTSD

How the next psychedelics companies believe they can avoid Lykos’ fate

Atai’s DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant

Atai advances oral psychedelic in depression

Atai Touts Early Data on Psychedelic Depression Drug, Plans Phase II Trial

FDA rejected MDMA-assisted PTSD therapy. Other psychedelics firms intend to avoid that fate

Sergey Brin is using money from selling his Tesla shares to bankroll a startup developing hallucinogenic mental-health treatments

In strengthening Spravato sales, a positive sign for psychedelic drugs

Trouble for ecstasy? What MDMA’s FDA setback could mean for psychedelics

Psychedelic Therapies Could Soon Break Through Against Addiction

Atai Life Sciences spotlights early depression data for psychedelic ahead of big readout